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Abstract
Background: Recently, the prognostic significance of circulating tumor cells (CTCs) in primary breast cancer as
assessed using the Food-and-Drug-Administration-approved CellSearch® system has been demonstrated. Here, we
evaluated the prognostic relevance of CTCs, as determined using manually performed immunocytochemistry
(MICC) in peripheral blood at primary diagnosis, in patients from the prospectively randomized multicenter
SUCCESS-A trial (EudraCT2005000490-21).
Methods: We analyzed 23 ml of blood from 1221 patients with node-positive or high risk node-negative breast
cancer before adjuvant taxane-based chemotherapy. Cells were separated using a density gradient followed by
epithelial cell labeling with the anti-cytokeratin-antibody A45-B/B3, immunohistochemical staining with new fuchsin,
and cytospin preparation. All cytospins were screened for CTCs, and the cutoff for positivity was at least one CTC.
The prognostic value of CTCs with regard to disease-free survival (DFS), distant disease-free survival (DDFS),
breast-cancer-specific survival (BCSS), and overall survival (OS) was assessed using both univariate analyses
applying the Kaplan–Meier method and log-rank tests, and using multivariate Cox regressions adjusted for other
predictive factors.
Results: In 20.6 % of all patients (n = 251) a median of 1 (range, 1–256) CTC was detected, while 79.4 % of the
patients (n = 970) were negative for CTCs before adjuvant chemotherapy. A pT1 tumor was present in 40.0 % of
patients, 4.8 % had G1 grading and 34.6 % were node-negative. There was no association between CTC positivity
and tumor stage, nodal status, grading, histological type, hormone receptor status, Her2 status, menopausal status or
treatment. Univariate survival analyses based on a median follow-up of 64 months revealed no significant differences
between CTC-positive and CTC-negative patients with regard to DFS, DDFS, BCSS, or OS. This was confirmed by fully
adjusted multivariate Cox regressions, showing that the presence of CTCs (yes/no) as assessed by MICC did not predict
DFS, DDFS, BCSS or OS.
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Conclusions: We could not demonstrate prognostic relevance regarding CTCs that were quantified using the MICC
method at the time of primary diagnosis in our cohort of early breast cancer patients. Further studies are necessary to
evaluate if the presence of CTCs assessed using MICC has prognostic relevance, or can be used for risk stratification and
treatment monitoring in adjuvant breast cancer.
Trial registration: The ClinicalTrial.gov registration ID of this prospectively randomized trial is NCT02181101; the
(retrospective) registration date was June 2014 (study start date September 2005).
Keywords: Breast cancer, Circulating tumor cells, Manual immunocytochemistry, Disease-free survival, Overall survival,
Neoplasm, Neoplasm recurrence, Translational research, Detection method
Background
After having established disseminated tumor cells (DTCs)
in the bone marrow as a prognostic factor in metastatic
breast cancer [1, 2] in an adjuvant [3–9] and neoadjuvant
[10, 11] setting, circulating tumor cells (CTCs) in the per-
ipheral blood of metastatic breast cancer patients have
been more recently analyzed with respect to disease-free
survival (DFS) and overall survival (OS) by different study
groups [12–14]. A European pooled analysis involving
1944 patients with metastatic breast cancer has confirmed
the independent prognostic effect of CTCs [15]. CTCs are
believed to represent minimal residual disease (MRD)
after resection of the primary tumor, with the potential to
form distant metastases later in the course of the disease
[16, 17]. Accordingly, some recent studies have shown that
the presence of CTCs at the time of primary diagnosis is
associated with a poor prognosis, that is, reduced DFS as
well as shorter OS [18–21]. The independent prognostic
value of CTCs (as assessed using the FDA-approved Cell-
Search® system) in early breast cancer was confirmed in a
large pooled analysis of 3173 patients, which showed that
both DFS and OS were reduced significantly if CTCs were
present at the time of the primary diagnosis [22].
In addition to the CellSearch® system, there are several
other techniques available for the detection and enumer-
ation of CTCs [23]; however, data on the prognostic role
of CTCs as evaluated using these alternative methods in
early breast cancer are lacking, whereas detection of
DTCs in bone marrow using cytokeratin-based manual
immunocytochemistry (MICC) is well established and
has shown prognostic relevance.
The aim of the present study was to evaluate the prog-
nostic relevance of CTCs, as detected by MICC at the time
of primary diagnosis, for disease recurrence and survival in
a large patient cohort from the SUCCESS-A trial.
Methods
Study design
The SUCCESS-A study is a prospectively randomized
German multicenter open label phase III trial, investigat-
ing the potential benefit of gemcitabine in the adjuvant
treatment of primary breast cancer patients. A total of
3754 node-positive or high-risk node-negative patients
were randomized to either 3 cycles of FEC followed by
3 cycles of docetaxel or 3 cycles of FEC followed by 3 cycles
of docetaxel plus gemcitabine. The study was approved by
all involved ethical boards in Germany (reference number
076–05), and written informed consent was obtained from
all study participants.
Patients and procedures
Patient and tumor characteristics were collected for all
participants of the trial recruited in 251 German study
centers. The tumor stage at primary diagnosis was classi-
fied according to the revised AJCC tumor-node-metastasis
(TNM) classification [24]. Histopathological grading of the
primary tumors was assessed according to the Bloom–
Richardson system. Tumors for which immunohistochem-
ical nuclear staining for estrogen, progesterone, or both
yielded ≥10 % stained cells were classified as hormone
receptor-positive. HER2 positivity was assigned if strong
(3+) immunohistochemical membranous staining was
present or, in the case of moderate (2+) membranous
staining, if an additional fluorescence in situ hybridization
(FISH) analysis yielded a positive test result. All patients
underwent primary breast surgery (either breast conserva-
tion therapy or modified radical mastectomy) leading to
R0 resection. Routine axillary dissection in patients with
positive sentinel lymph nodes included levels I and II.
Only when macroscopic metastatic involvement of these
lymph nodes was also present, level III lymph nodes were
excised. For the diagnosis of lymph node metastasis, single
embedded lymph nodes were screened at up to three
levels. External beam radiation therapy was administered
to all patients treated with breast conserving surgery.
Chest wall irradiation following mastectomy was per-
formed in patients with >3 involved lymph nodes or T3
and T4 tumors. After the end of chemotherapy (either
FEC-Doc or FEC-Doc/Gemcitabine), premenopausal pa-
tients with hormone receptor-positive disease received
tamoxifen for 5 years. Endocrine treatment of postmeno-
pausal patients started with tamoxifen for 2 years and was
continued with anastrozole for another 3 years.
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Blood sample collection, blood preparation and
immunocytochemistry
According to the SUCCESS-A study protocol, blood
samples had to be taken from each patient before the
start of adjuvant chemotherapy. Usually, CTC detec-
tion was performed using the CellSearch® system;
however, in cases where too little blood was available
for the CellSearch® analysis, or if there was a surplus
of blood, CTC detection was performed using the
MICC method.
For the study presented here, blood samples (23 ml)
from 1221 of the 3754 patients with histologically con-
firmed invasive primary breast cancer recruited for the
SUCCESS-A trial were collected and analyzed using the
MICC method; written informed consent was obtained
from each patient. If the time span between the collec-
tion and preparation of blood samples exceeded 96 h pa-
tients were excluded from the analysis. Peripheral blood
was collected in tubes containing ethylene diamine tetra
acetate (EDTA) and in some cases, also a cell-stabilizing
agent (Veridex, Janssen Diagnostics, Raritan, NJ, USA).
Samples were shipped at room temperature to the central
cancer immunological laboratory at the Women’s Hospital
of the Ludwig Maximilians-University of Munich. Blood
analyses were performed according to the previously
published semi-quantitative assay for bone marrow
preparation [25], with the exception of cell enrichment
via density gradient centrifugation (OncoQuick® tech-
nique), which was performed according to a standard
protocol provided by the manufacturer (Greiner BioOne,
Frickenhausen, Germany). Here both a liquid separation
medium and the subsequent density gradient centrifuga-
tion ensured separation of blood cells and granulocytes
and specific enrichment of CTCs.
Tumor cell isolation and detection was accomplished
based on the Consensus Recommendations [25, 26].
After two centrifugation steps at 500 rpm for 5 min at
room temperature, washing (and if needed lysis of red
blood cells) and cytospins were prepared by spinning the
remaining mononuclear cells onto microscope slides
(1,000,000 cells per slide; Menzel, Braunschweig, Germany).
The cytospins were air-dried for ≥12 h at room
temperature and then used immediately or stored at
room temperature.
Immunostaining of cytospins from the blood prepara-
tions using the pan-anti-cytokeratin monoclonal antibody
A45-B/B3 has been described in detail elsewhere [27]. To
detect the specific reaction of the primary antibody, the
DAKO- alkaline phosphatase-anti-alkaline phosphatase
(APAAP) detection system with the Z0259 antibody serv-
ing as a secondary antibody (DakoCytomation, Glostrup,
Denmark) combined with new fuchsin staining was used.
After capping with cover slips the cytospins were stored at
room temperature.
Cytospins containing MCF-7 cells [28] were used as
positive controls while cytospins with murine antibody
mouse IgG1 kappa (MOPC 21: Sigma, Deisenhofen,
Germany) served as negative controls. A total of three
cytospins (two cytospins for the detection of CTCs and
one negative control) were prepared from all of the
blood samples (2 × 106 cells per sample). All cytospins
were manually screened for CTCs using conventional light
field microscopy (Axiophot: Zeiss, Oberkochen, Germany)
or using an automatic device (MDS 1: Applied Imaging
Corp., Santa Clara, California, USA) by two independent
investigators (Fig. 1). First, cytospins were screened at 20-
fold magnification to localize cells suspected of being
CTCs; the identity of these cells was then validated by ob-
servation at 63-fold magnification. The determination of
the presence of CTCs was based on Consensus Criteria,
and only immunocytochemically positive cells lacking
hematopoietic characteristics, with a moderate to strong
staining intensity, were defined as CTCs. Additional cri-
teria for positivity were pathognomonic signs of epithelial
tumors, as defined by a clearly enlarged nucleus or
clusters of ≥ 2 immunopositive cells [26, 29].
Statistical analysis
For all categorical variables, descriptive statistics are pro-
vided in terms of absolute and relative frequencies. Con-
tinuous variables showing data distributions that differed
significantly from a normal distribution (as assessed
using the Shapiro–Wilk test) are described by reporting
medians and ranges. Associations between the presence
Fig. 1 Light-field microscopic image of a circulating tumor cell (CTC)
detected using manual immunocytochemistry. Unstained blood cells
are visible around the stained CTC
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of CTCs and patients as well as tumor characteristics
were analyzed using the following tests: the Mann–
Whitney U test for non-normally distributed continuous
variables; the Cochran–Armitage test for trends in the
ordered categorical variables tumor stage; nodal stage
and grading; and the chi-square test for all other categor-
ical variables. These analyses are not part of the primary
study objective and have to be interpreted as explorative
analyses only; shown are uncorrected p-values.
We performed separate analyses for the four survival
endpoints, namely OS, BCSS, DFS and distant disease-
free survival (DDFS), with the survival endpoints being
defined according to the STEEP criteria [30]. Time-to-
event data were analyzed using the Kaplan–Meier method
and summarized using medians, 95 % confidence limits
and Kaplan–Meier survival plots. All time-to-event inter-
vals were measured from the time of the primary diagnosis
to the date of the event. If no event was documented,
the data were censored at the date of the last adequate
follow-up. To assess the simultaneous effects of multiple
covariates on the survival endpoints we used Cox
proportional-hazards regression models. The initial
model included age, tumor stage, nodal stage, tumor
grade, histological type, hormone receptor status, HER2
status and menopausal status. We then performed a step-
wise backward selection procedure to exclude variables
that did not significantly contribute to the model (signifi-
cance level cutoff for exclusion, 0.10; significance assessed
based on the likelihood ratio test), resulting in a final
model without the variable CTC presence. In the last step,
CTC presence (yes/no) was added to this final model to
determine whether or not the inclusion of this variable
significantly improved the model, that is, whether the
presence of CTCs was a significant independent prognos-
tic factor for survival.
All statistical tests were two-sided, and p values of < 0.05
were considered significant. Statistical analyses were per-
formed using IBM SPSS Statistics, Version 21.0 software
(IBM Corp., Armonk, New York, USA).
Results
Patient characteristics
The median age of the 1221 patients included in this
study was 53 (range, 22–85) years and 42.7 % (n = 521)
were premenopausal women. More than half of the pa-
tients (60.0 %) had tumors >2 cm in size; the vast major-
ity (95.1 %) had grade G2 or G3 tumors, and most of the
patients (65.2 %) were node positive. Nearly all of the tu-
mors belonged to the ductal histological subtype (83.5 %),
while only 10.0 % of lobular and 6.6 % of other subtypes
were found. Overall, 69.7 % of the patients had a hormone
receptor-positive tumor, and 24.2 % of the patients showed
overexpression of the HER2 gene.
All patients underwent a surgical procedure resulting
in R0-resection of their tumor prior to entering the
study. Breast conserving surgery was performed in 71.7 %
of the patients. In 99.7 % of patients, axillary lymph nodes
were excised (in 21.9 % by means of a sentinel lymph node
dissection), and only 0.3 % did not receive any axillary sta-
ging. All of the patients received adjuvant chemotherapy
according to the study protocol. In 85.6 % of the patients,
radiation therapy was performed after the end of chemo-
therapy, and 72.6 % of the patients underwent endocrine
treatment. More details regarding patient and tumor char-
acteristics as well as the treatments received are given in
Table 1.
Prevalence of CTCs before chemotherapy
Collection of peripheral blood was performed not later
than 6 weeks after primary diagnosis and R0-resection
of the tumor, but always before the commencement of
adjuvant chemotherapy. The majority of the patients
(n = 970; 79.4 %) were negative for CTCs at primary
diagnosis. The median number of detected CTCs for
the 251 (20.6 %) CTC-positive patients was 1 (range,
1–256) (Fig. 2).
CTC status according to patient characteristics, tumor
biology, and therapy
The presence of CTCs in the peripheral blood after re-
section of the primary tumor, but before adjuvant
chemotherapy, was not significantly associated with pa-
tient characteristics (age and menopausal status), tumor
characteristics (tumor stage, lymph node status, grading,
histological type, hormone receptor status and HER2
status), surgical procedures (breast conserving therapy
vs. mastectomy), or therapeutic regimens (Table 1).
Impact of CTC status on overall and breast-cancer-specific
survival
The median follow-up time was 64 months from primary
diagnosis. Overall, 109 (8.9 %) out of the 1221 patients
died during follow-up, and 94 of the deaths were breast-
cancer specific. A total of 79 (8.1 %) of the 970 patients
without CTCs at the time of primary diagnosis and 30
(12.0 %) of the 251 patients with CTCs died. Univariate
survival analyses revealed a trend for shorter OS in pa-
tients with CTCs (hazard ratio (HR), 1.47; 95 % confidence
interval (CI), 0.96–2.23; log-rank test, p = 0.07; Fig. 3a).
Breast-cancer-specific deaths occurred in 68 (7.0 %) pa-
tients without CTCs and in 26 (10.4 %) patients with
CTCs; similar to OS, univariate survival analysis indicated
a trend towards shortened breast-cancer-specific survival
in CTC positive patients (HR, 1.48; 95 % CI, 0.94–2.33;
log-rank test, p = 0.09; Fig. 3b). However, in multivariate
analyses, only tumor stage, nodal stage, hormone-receptor
status, and HER2 status significantly predicted OS, while
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Table 1 Baseline characteristics of patients and prevalence of circulating tumor cells (CTCs) according to clinicopathological variables
Variable All patients N = 1221 Patients without CTCs N = 970 Patients with CTCs N = 251 p-valuea
Age (years) 0.41b
Median 53.0 53.0 54.0
Range 22 - 85 22 - 85 33 - 75
Tumor stage 0.34c
pT1 489 (40.0 %) 397 (40.9 %) 92 (36.7 %)
pT2 652 (53.4 %) 511 (52.7 %) 141 (56.2 %)
pT3 63 (5.2 %) 47 (4.8 %) 16 (6.4 %)
pT4 17 (1.4 %) 15 (1.5 %) 2 (0.8 %)
Nodal stage 0.23c
pN0 422 (34.6 %) 341 (35.2 %) 81 (32.3 %)
pN1 561 (45.9 %) 446 (46.0 %) 115 (45.8 %)
pN2 165 (13.5 %) 126 (13.0 %) 39 (15.5 %)
pN3 70 (5.7 %) 54 (5.6 %) 16 (6.4 %)
unknown 3 (0.2 %) 3 (0.3 %) 0 (0.0 %)
Histological grading 0.30c
G1 59 (4.8 %) 43 (4.4 %) 16 (6.4 %)
G2 604 (49.5 %) 479 (49.4 %) 125 (49.8 %)
G3 557 (45.6 %) 447 (46.1 %) 110 (43.8 %)
unknown 1 (0.1 %) 1 (0.1 %) 0 (0.0 %)
Histological type 0.26d
ductal 1019 (83.5 %) 812 (83.7 %) 207 (82.5 %)
lobular 122 (10.0 %) 91 (9.4 %) 31 (12.4 %)
other 80 (6.6 %) 67 (6.9 %) 13 (5.2 %)
Hormone receptor status 0.73d
negative 368 (30.1 %) 290 (29.9 %) 78 (31.1 %)
positive 851 (69.7 %) 678 (69.9 %) 173 (68.9 %)
unknown 2 (0.2 %) 2 (0.2 %) 0 (0.0 %)
HER2 status 0.88d
negative 906 (74.2 %) 720 (74.2 %) 186 (74.1 %)
positive 296 (24.2 %) 234 (24.1 %) 62 (24.7 %)
unknown 19 (1.6 %) 16 (1.6 %) 3 (1.2 %)
Menopausal status 0.88d
premenopausal 521 (42.7 %) 415 (42.8 %) 106 (42.2 %)
postmenopausal 700 (57.3 %) 555 (57.2 %) 145 (57.8 %)
Type of surgery 0.27d
breast conserving 876 (71.7 %) 703 (72.5 %) 173 (68.9 %)
mastectomy 345 (28.3 %) 267 (27.5 %) 78 (31.1 %)
Radiotherapy 1.00d
no 175 (14.3 %) 139 (14.3 %) 36 (14.3 %)
yes 1045 (85.6 %) 830 (85.6 %) 215 (85.7 %)
unknown 1 (0.1 %) 1 (0.1 %) 0 (0.0 %)
Endocrine therapy 0.81d
no 333 (27.3 %) 266 (27.4 %) 67 (26.7 %)
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the final model for breast-cancer-specific survival add-
itionally included tumor grade (Table 2). The addition of
CTC status to the model did not significantly improve
model fit (p = 0.14 and p = 0.17, respectively; Table 2);
thus, we could not show that CTC status was an inde-
pendent prognostic factor for OS or breast-cancer-specific
survival.
Impact of CTC status on disease recurrence
Breast cancer recurred in 172 (14.1 %) patients during
the follow-up period, with 130 (13.4 %) relapses in the
970 patients without CTCs and 42 (16.7 %) relapses in
the 251 patients with CTCs. Distant metastases occurred
in 90 (9.3 %) patients without CTCs and in 32 (12.7 %)
patients with CTCs. Univariate analyses showed that
CTC status was not significantly associated with DFS
(HR, 1.25; 95 % CI, 0.88–1.77; log-rank test, p = 0.21;
Fig. 3c) or DDFS (HR, 1.40; 95 % CI, 0.94–2.10; log-rank
test, p = 0.10; Fig. 3d). Multivariate analyses confirmed
the lack of significant prognostic relevance regarding
CTC presence at the time of primary diagnosis for dis-
ease recurrence; this was because the addition of CTC
status to the final model obtained after backward selec-
tion did not significantly improve model fit, both for
DFS (p = 0.34) and DDFS (p = 0.17). The only significant
predictors for DFS in our analyses were tumor stage,
nodal stage, hormone-receptor status, and HER2 status,
while the final model for DDFS included age, tumor
stage, nodal stage, hormone-receptor status, and meno-
pausal status (Table 2).
Discussion
This is the largest analysis of the prognostic role of
CTCs detected using MICC in the setting of a prospect-
ively randomized multicenter trial in early breast cancer
patients before adjuvant chemotherapy. However, our
Table 1 Baseline characteristics of patients and prevalence of circulating tumor cells (CTCs) according to clinicopathological variables
(Continued)
yes 887 (72.6 %) 703 (72.5 %) 184 (73.3 %)
unknown 1 (0.1 %) 1 (0.1 %) 0 (0.0 %)
HER2-targeted therapy 0.54d
no 965 (79.0 %) 770 (79.4 %) 195 (77.7 %)
yes 255 (20.9 %) 199 (20.5 %) 56 (22.3 %)
unknown 1 (0.1 %) 1 (0.1 %) 0 (0.0 %)
aAll tests without unknowns
bMann–Whitney U test
cCochran–Armitage test for trend
dChi-square test
Fig. 2 Frequency distribution of the number of circulating tumor cells (CTCs). CTCs were detected using manual immunocytochemistry in the
peripheral blood of 1221 patients with early breast cancer at the time of primary diagnosis (before the start of adjuvant chemotherapy)
Jueckstock et al. BMC Cancer  (2016) 16:401 Page 6 of 11
investigation did not show an association between the
presence of CTCs detected using MICC in the periph-
eral blood and earlier disease recurrence or reduced sur-
vival time. These results are surprising in the context of
previous findings obtained in another patient cohort of
the same large prospective, randomized multicenter trial
(the German SUCCESS-A trial). Using the FDA ap-
proved CellSearch® system to assess CTC prevalence at
the time of primary diagnosis in 2026 breast cancer pa-
tients, Rack et al. demonstrated the presence of CTCs to
be a highly significant and independent prognostic factor
for OS and DFS with multivariate hazard ratios of 2.18
for OS and 2.11 for DFS [20].
A comparison of CTC prevalence in patients from the
SUCCESS-A trial assessed using either the CellSearch®
system or MICC revealed that the proportion of patients
with CTCs in the peripheral blood at the time of pri-
mary diagnosis, as detected using the two methods, did
not differ significantly (21.1 % vs. 20.6 %; p = 0.75); fur-
thermore, the two patient cohorts were found to be
well-balanced with regard to clinicopathological parame-
ters [31]. Thus, it might be expected that the presence of
CTCs should be associated with a worse outcome for all
patients in the SUCCESS-A study, regardless of the
method for CTC detection. Our finding that the pres-
ence of CTCs as detected using the MICC method was
not significantly associated with reduced survival (in
contrast to the presence of CTCs as detected with the
CellSearch® system) indicates that the CellSearch® system
might be superior to the MICC method in terms of the
detection of prognostically relevant CTCs. However, even
if the patient cohorts were comparable and well balanced,
the two groups were not equivalent and comprised
different patients; this hindered a direct comparison
between the two methods and interpretation of the results
obtained. Head-to-head comparisons between the two
methods regarding the same samples could not be per-
formed because of the very small patient number (n = 22)
for which both CTC detection methods (CellSearch® and
MICC) were used. Thus, there could be other as yet un-
identified differences between the two patient cohorts that
account for the fact that the presence of CTCs was associ-
ated with a significantly poorer prognosis in patients
where CTC prevalence was determined using the Cell-
Search® system, but not in patients where CTC prevalence
was determined using the MICC method. Other possible
Fig. 3 Kaplan–Meier plots of survival. a overall survival, b breast cancer-specific survival, c disease-free survival and d distant disease-free survival
according to the absence (n = 970) or the presence (n = 251) of CTCs in the peripheral blood at the time of primary diagnosis. HR denotes the
hazard ratio, and p-values refer to log-rank tests
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explanations for the differing results are pre-analytical fac-
tors caused by the fact that for the MICC method patients
were chosen from whom too little blood was available to
perform the CellSearch® analysis. The fact that we found
no significant association between the presence of CTCs
detected using the MICC method and survival, was not
the result of a lack of statistical power; a retrospective
power analysis showed that our study had 95 % power
(two-sided, alpha 0.05) in the detection of a DFS hazard
ratio of 2.0 for patients with CTCs relative to patients
without CTCs. For comparison, the univariate DFS hazard
ratio for the SUCCESS-A patients with CTCs detected
using the CellSearch® system, as compared with patients
without CTCs as reported by Rack et al. [20], was 2.26.
Thus, we are confident that our study was sufficiently
powered to detect a prognostic value of CTCs assuming a
hazard ratio similar to the one reported by Rack et al. [20].
In our view, the most probable explanation for the incon-
gruent findings of the current study as compared with the
previous analysis [20] is that the two methods differ with
regard to the subpopulations of circulating cells that
are detected, even if we cannot completely exclude the
possibility that the observed differences are caused by
an unidentified bias between the two patient cohorts.
Both the CellSearch® system and the MICC technique
are based on labeling of cytokeratin-containing cells
(and therefore epithelial cells) in peripheral blood [32].
Using the CellSearch® system CTCs are separated from
blood cells on the basis of epithelial cell adhesion mol-
ecule (EpCam) expression, while in the MICC method
this separation is achieved using a density gradient cen-
trifugation. Former investigations in healthy individuals
and in patients with benign tumors as compared with
patients with malignant tumors [33] have shown the high
specificity of the CellSearch® system in reliably detecting
malignant epithelial cells. The carcinomatous origin of the
detected CTCs using the MICC method has also been
proven [34]. One difference between the two techniques is
that the CellSearch® system is a semi-automated method
while the MICC technique is performed manually. Conse-
quently, the MICC technique is the more elaborate and
time-consuming process; as a manual technique it has
a higher intertest variability concerning CTC detection
in peripheral blood. However, the final decision as to
Table 2 Multivariate hazard ratios (HR) for overall, breast cancer-specific, disease-free, and distant disease-free survival
Overall survival Breast-cancer-specific survival Disease-free survival Distant-disease-free survival
HR 95 % CI p-value HR 95 % CI p-value HR 95 % CI p-value HR 95 % CI p-value
Final Model (without CTC presence):
Age – – – – – – – – – 0.96 0.94 – 0.99 0.007
Tumor stage <0.001 <0.001 0.001 0.001
T2 vs. T1 1.43 0.92 – 2.21 0.11 1.70 1.04 – 2.78 0.03 1.21 0.86 – 1.69 0.27 1.35 0.90 – 2.03 0.15
T3 vs. T1 1.97 0.95 – 4.08 0.07 2.78 1.29 – 5.97 0.01 1.35 0.73 – 2.50 0.35 1.22 0.56 – 2.65 0.62
T4 vs. T1 9.33 4.01 – 21.69 <0.001 9.98 3.92 – 25.40 <0.001 5.25 2.35 – 11.73 <0.001 6.88 2.62 – 18.06 <0.001
Nodal stage <0.001 <0.001 <0.001 <0.001
N1 vs. N0 1.49 0.91 – 2.45 0.11 1.85 1.08 – 3.18 0.03 1.53 1.03 – 2.27 0.03 2.17 1.32 – 3.57 0.002
N2 vs. N0 1.69 0.92 – 3.10 0.09 1.80 0.92 – 3.50 0.09 1.90 1.18 – 3.06 0.01 3.35 1.89 – 5.96 <0.001
N3 vs. N0 6.66 3.57 – 12.42 <0.001 8.59 4.42 – 16.68 <0.001 6.65 3.98 – 11.10 <0.001 10.76 5.82 – 19.89 <0.001
Hormone receptor status
pos vs. neg 0.31 0.20 – 0.46 <0.001 0.27 0.16 – 0.43 <0.001 0.35 0.25 – 0.49 <0.001 0.32 0.22 – 0.46 <0.001
Her2 status
pos vs. neg 0.59 0.36 – 0.95 0.03 0.58 0.35 – 0.96 0.04 0.70 0.48 – 1.02 0.06 - - -
Grading - 0.21 - -
G2 vs. G1 - - - 4.85 0.66 – 35.49 0.12 - - - - - -
G3 vs. G1 - - - 5.71 0.78 – 41.80 0.09 - - - - - -
Menopausal status
post vs. pre - - - - - - - - - 1.66 0.92 – 2.99 0.09
Addition of CTC presence
CTCs
pos vs. neg 1.38 0.91 – 2.11 0.14 1.39 0.88 – 2.20 0.17 1.19 0.84 – 1.69 0.34 1.34 0.89 – 2.02 0.17
Shown is the final model (Cox proportional hazards regression model, without CTC presence) after backward selection (see text), and the parameter estimates, as
well as the significance of the change when CTC presence (yes/no) was added to the model. Please note that the addition of CTC presence did not significantly
improve model fit for any of the four analyzed survival endpoints
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whether or not a cell is considered a CTC using both
techniques has to be made by an investigator, and cannot
be carried out using an automated method. Another im-
portant difference is that the MICC method does not have
a CD 45 counterstaining step for the separation of leuko-
cytes from CTCs; thus, it possibly yields a higher amount
of prognostically less relevant cells (such as leukocytes)
that impair the prognostic value of this method. In brief,
the main differences between MICC and the CellSearch®
are as follows: the cell enrichment is achieved via density
gradient centrifugation using MICC and with an auto-
mated cell enrichment method using the CellSearch® sys-
tem; the APAAP technique is applied for antibody staining
using MICC and immunomagnetic antibody enrichment
using CellSearch® (however, both methods use the same
antibodies directed against cytokeratins CK8, CK18, and
CK19); and the lack of CD 45 counterstaining in the
MICC method. Thus, it seems possible that some of the
observed inconsistent findings with regard to CTCs de-
tected with the CellSearch® system or the MICC method
might be related to technical details or procedures.
In bone marrow analyses concerning DTCs, the MICC
method is considered the gold standard because of its
high reliability and reproducibility [25]. However, with
respect to the detection of CTCs in the peripheral blood,
the CellSearch® system seems to be more reliable and
represents the most established method, especially with
regard to the evaluation of the prognostic value of CTCs.
There have been some studies that have compared the
CellSearch® system with other methods for CTC detection
and enumeration. In a direct comparison based on blood
samples collected from 61 patients with metastatic and
non-metastatic cancer, as well as 15 healthy donors, the
CellSearch® system proved to be more sensitive than a
manual detection technique using OncoQuick®. CTCs
were detected in 33 (54 %) out of the 61 cancer patients
using the CellSearch® system, but in only 14 (23 %) of
these patients using OncoQuick® [35]. Interestingly, con-
sidering only patients with non-metastatic cancer, the de-
tection rate of CTCs was equal using both methods
(12 %); it was considerably lower than the detection rate
found in our study (20.6 %). However, it should be noted
that the staining process (DAPI, Alexa Fluor 555) used in
the study by Balic et al. [35] differs from the staining
method (CK, new fuchsin) used in our analysis. Using an-
other fluorescence based detection method Pachmann et
al. also demonstrated the prognostic relevance of CTCs in
primary breast cancer patients [36]. A study comparing
three different CTC detection methods in metastatic
breast cancer patients found that a molecular technique
based on a combined quantitative reverse-transcription
polymerase chain reaction (qRT-PCR) approach for
CK-19 and mammaglobin was more sensitive than the
CellSearch® system or the AdnaTest BreastCancer®, which
is another commercially available CTC assay based on
the detection of three tumor-associated transcripts
(GA733-2, MUC-1, and HER2) using the reverse tran-
scription-polymerase chain reaction (RT-PCR) after
immunomagnetic enrichment of tumor cells [37]. Two
more studies compared the AdnaTest BreastCancer® with
the CellSearch® system in patients with metastatic breast
cancer. One study revealed a high concordance between
the AdnaTest BreastCancer® and the CellSearch® system in
the detection of two or more CTCs without evaluating the
prognostic relevance [38]. In contrast, the prospective
multicenter German DETECT study showed a higher
positivity rate for CTCs using the CellSearch® System
(cutoff level ≥5 CTCs; 122 out of 245; 50 %) compared
to the AdnaTest BreastCancer® (88 out of 221; 40 %) [39].
Furthermore, CTC positivity assessed based on the Cell-
Search® system was found to be a significant prognostic
factor for OS in both univariate and multivariate analyses
(HR, 2.7; 95 % CI, 1.6–4.2; p < 0.01), while CTC-positivity
assessed using the AdnaTest BreastCancer® had no signifi-
cant association with progression-free survival (PFS) or
OS [39]. In summary, in comparing different CTC detec-
tion methods, the FDA approved CellSearch® system
seems to be one of the most reliable techniques; however,
the MICC method is still considered the gold standard re-
garding DTC detection in the bone marrow.
Conclusions
To our knowledge, no direct comparison of different
manual detection methods for CTCs has been previously
reported; thus, until now no conclusion can be drawn as
to which of the manually performed CTC analyses is the
most reliable method. Here, we could not demonstrate
the prognostic relevance of CTCs detected using MICC
in early breast cancer patients. This contrasts with the
findings of Rack et al. [20] and Lucci et al. [21], who re-
ported that CTC positivity as assessed using the Cell-
Search® system was significantly associated with reduced
PFS and OS. Our results show that the presence of CTCs
as assessed using manual detection methods is not associ-
ated with survival; they also indicate that, although not ne-
cessarily the most sensitive technique, the CellSearch®
system seems to be the more reliable method concerning
the detection of prognostically relevant CTCs in early and
metastatic breast cancer.
Abbreviations
APAAP, alkaline phosphatase-antialkaline phosphatase; BCSS, breast-cancer-
specific survival; CI, confidence interval; CK, cytokeratin; CTC, circulating
tumor cells; DDFS, distant-disease-free survival; DFS, disease-free survival;
DTC, disseminated tumor cells; EDTA, ethylene diamine tetra acetate; EpCam,
epithelial cell adhesion molecule; FDA, food and drug administration;
FISH, fluorescence in situ hybridization; HR, hazard ratio; MICC, manually
immunocytochemistry; MRD, minimal residual disease; OS, overall survival;
qRT-PCR, quantitative real time polymerase chain reaction; SUCCESS,
Jueckstock et al. BMC Cancer  (2016) 16:401 Page 9 of 11
Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment,
as well as Extended Bisphosphonate and Surveillance.
Acknowledgements
The clinical part of this study was funded by the pharmaceutical companies
AstraZeneca, Chugai, Lilly, Novartis, and Sanofi-Aventis. The translational
research within the trial was funded by Veridex. No funding source had any
influence on the design or conduct of the study; collection, management,
analysis or interpretation of the data; or preparation, review or approval of
the manuscript, nor on the decision to submit it for publication. The study
was conducted in cooperation with two German scientific-oncological societies,
the North-East German Society for Gynecological Oncology (NOGGO) and the
Association of Gynecologic Oncologists in Germany (BNGO) and was
recommended by the Research Group on Gynecological Oncology from
the German Cancer Society (AGO). The opinions, results and conclusions
reported in this paper are those of the authors and are independent from
the funding sources. The authors would like to thank all of the 1221 study
participants who gave their blood for investigational purposes. In addition,
we would like to thank Cornelia Lieb-Lundell for her linguistic support.
Funding
The SUCCESS-A study was funded by AstraZeneca, Chugai, Lilly, Novartis, and
Sanofi-Aventis.
The translational research that was part of this trial was funded by Veridex.
Availability of data and materials
The dataset supporting the conclusions of this article is stored in the CRO’s
data repository and is available on request (https://www.alcedis.de).
All blood samples used for the detection of CTCs were processed at the
laboratory of the Frauenklinik Innenstadt, Munich University. The cytospins
used for detection with the MICC method as well as the electronically
archived data generated using the CellSearch® system are stored at this
laboratory.
Authors’ contributions
JJ carried out the MICC analyses, was involved in the data collection and
conduction of the SUCCESS-A trial, and created the manuscript. BR, MWB,
WL, and WJ participated in the conception and design of the SUCCESS-A
study, were involved in the coordination of the trial as well as in the analysis
and interpretation of the data, and helped in the drafting and editing of the
manuscript. CS, JN, ET, HT, HF, RL, MR, MA-F, AS, PAF, and KP helped conduct
the study including the analysis and interpretation of the data; they also edi-
ted the manuscript. TWPF and LH performed the statistical analyses and
helped in the drafting the manuscript. All authors read and approved the
final manuscript.
Competing interests
BR and WJ received research funding from AstraZeneca, Chugai, Lilly,
Novartis, and Sanofi-Aventis. The other authors declare that they have no
competing interests.
Consent for publication
All study participants gave informed consent allowing publication of their
anonymized data. No individual patient data is content of this manuscript.
Ethics approval and consent to participate
The study was conducted according to the Declaration of Helsinki and the
protocol as well as the informed consent document have been approved by
the ethical review board of the University of Munich (Ethikkommission der
Medizinischen Fakultaet der Ludwig-Maximilians-Universitaet Muenchen),
project number 076-05.
Author details
1Department of Gynecology and Obstetrics, Ludwig-Maximilians-University,
Munich, Germany. 2Department of Gynecology and Obstetrics, University
Hospital Ulm, Ulm, Germany. 3Oncology Bethanien, Frankfurt, Germany.
4Haemotologic-Oncologic Practice Dres, Forstbauer/Ziske, Troisdorf, Germany.
5Oncologic Practice Dres, Lorenz/Hecker/Wesche, Braunschweig, Germany.
6Luisenkrankenhaus, Duesseldorf, Germany. 7Department of Gynecology and
Obstetrics, University Erlangen, Erlangen, Germany. 8University of Heidelberg,
Heidelberg, Germany. 9Charité University Hospital, Berlin, Germany. 10Institute
for Tumor Biology, Hamburg University, Hamburg, Germany.
Received: 4 September 2015 Accepted: 28 June 2016
References
1. Kasimir-Bauer S et al. A summary of two clinical studies on tumor cell
dissemination in primary and metastatic breast cancer: methods, prognostic
significance and implication for alternative treatment protocols (Review). Int
J Oncol. 2002;20(5):1027–34.
2. Braun S, Auer D, Marth C. The prognostic impact of bone marrow
micrometastases in women with breast cancer. Cancer Invest. 2009;27(6):598–603.
3. Falck AK et al. Analysis of and prognostic information from disseminated
tumour cells in bone marrow in primary breast cancer: a prospective
observational study. BMC Cancer. 2012;12:403.
4. Janni W et al. Persistence of disseminated tumor cells in the bone marrow
of breast cancer patients predicts increased risk for relapse–a European
pooled analysis. Clin Cancer Res. 2011;17(9):2967–76.
5. Domschke C, et al. Prognostic Value of Disseminated Tumor Cells in the
Bone Marrow of Patients with Operable Primary Breast Cancer: A Long-term
Follow-up Study. Ann Surg Oncol. 2013;20(6):1865–71.
6. Synnestvedt M et al. Disseminated tumor cells as selection marker and
monitoring tool for secondary adjuvant treatment in early breast cancer.
Descriptive results from an intervention study. BMC Cancer. 2012;12(1):616.
7. Janni W et al. The persistence of isolated tumor cells in bone marrow from
patients with breast carcinoma predicts an increased risk for recurrence.
Cancer. 2005;103(5):884–91.
8. Braun S et al. A pooled analysis of bone marrow micrometastasis in breast
cancer. N Engl J Med. 2005;353(8):793–802.
9. Hartkopf AD, et al. Disseminated tumor cells from the bone marrow of
patients with nonmetastatic primary breast cancer are predictive of
locoregional relapse. Ann Oncol. 2015;26(6):1155–60.
10. Hall C et al. Disseminated tumor cells predict survival after neoadjuvant
therapy in primary breast cancer. Cancer. 2012;118(2):342–8.
11. Mathiesen RR et al. Persistence of disseminated tumor cells after
neoadjuvant treatment for locally advanced breast cancer predicts poor
survival. Breast Cancer Res. 2012;14(4):R117.
12. Cristofanilli M et al. Circulating tumor cells, disease progression, and survival
in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91.
13. Hayes DF, Smerage JB. Circulating tumor cells. Prog Mol Biol Transl Sci.
2010;95:95–112.
14. Botteri E et al. Modeling the relationship between circulating tumour cells
number and prognosis of metastatic breast cancer. Breast Cancer Res Treat.
2010;122(1):211–7.
15. Bidard FC et al. Clinical validity of circulating tumour cells in patients with
metastatic breast cancer: a pooled analysis of individual patient data. Lancet
Oncol. 2014;15(4):406–14.
16. Muller V, Alix-Panabieres C, Pantel K. Insights into minimal residual disease
in cancer patients: implications for anti-cancer therapies. Eur J Cancer.
2010;46(7):1189–97.
17. Ignatiadis M, Reinholz M. Minimal residual disease and circulating tumor
cells in breast cancer. Breast Cancer Res. 2011;13(5):222.
18. Xenidis N et al. Cytokeratin-19 mRNA-positive circulating tumor cells after
adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol.
2009;27(13):2177–84.
19. Rack B et al. CTCs in primary breast cancer (I). Recent Results Cancer Res.
2012;195:179–85.
20. Rack B, et al. Circulating Tumor Cells Predict Survival in Early Average-to-
High Risk Breast Cancer Patients. J Natl Cancer Inst 2014;106(5).
21. Lucci A et al. Circulating tumour cells in non-metastatic breast cancer: a
prospective study. Lancet Oncol. 2012;13(7):688–95.
22. Janni W, et al. Pooled Analysis of the Prognostic Relevance of Circulating
Tumor Cells in Primary Breast Cancer. Clin Cancer Res. 2016;15;22(10):2583–93.
23. Parkinson DR et al. Considerations in the development of circulating tumor
cell technology for clinical use. J Transl Med. 2012;10:138.
24. Singletary SE et al. Revision of the American Joint Committee on Cancer
staging system for breast cancer. J Clin Oncol. 2002;20(17):3628–36.
25. Fehm T et al. A concept for the standardized detection of disseminated
tumor cells in bone marrow from patients with primary breast cancer and
its clinical implementation. Cancer. 2006;107(5):885–92.
Jueckstock et al. BMC Cancer  (2016) 16:401 Page 10 of 11
26. Borgen E et al. Immunocytochemical detection of isolated epithelial cells in
bone marrow: non-specific staining and contribution by plasma cells
directly reactive to alkaline phosphatase. J Pathol. 1998;185(4):427–34.
27. Wiedswang G et al. Isolated tumor cells in bone marrow three years after
diagnosis in disease-free breast cancer patients predict unfavorable clinical
outcome. Clin Cancer Res. 2004;10(16):5342–8.
28. Russo J et al. Reexpression of the original tumor pattern by a human
breast carcinoma cell line (MCF-7) in sponge culture. J Natl Cancer Inst.
1976;56(2):279–82.
29. Borgen E et al. Standardization of the immunocytochemical detection of
cancer cells in BM and blood: I. establishment of objective criteria for the
evaluation of immunostained cells. Cytotherapy. 1999;1(5):377–88.
30. Hudis CA et al. Proposal for standardized definitions for efficacy end
points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol.
2007;25(15):2127–32.
31. Jaeger BA et al. Evaluation of two different analytical methods for circulating
tumor cell detection in peripheral blood of patients with primary breast cancer.
Biomed Res Int. 2014;2014:491459.
32. Farace F et al. A direct comparison of Cell Search and ISET for circulating
tumour-cell detection in patients with metastatic carcinomas. Br J Cancer.
2011;105(6):847–53.
33. Allard WJ et al. Tumor cells circulate in the peripheral blood of all major
carcinomas but not in healthy subjects or patients with nonmalignant
diseases. Clin Cancer Res. 2004;10(20):6897–904.
34. Fehm T et al. Cytogenetic evidence that circulating epithelial cells in
patients with carcinoma are malignant. Clin Cancer Res. 2002;8(7):2073–84.
35. Balic M et al. Comparison of two methods for enumerating circulating
tumor cells in carcinoma patients. Cytometry B Clin Cytom. 2005;68(1):25–30.
36. Pachmann K et al. Detection and quantification of small numbers of
circulating tumour cells in peripheral blood using laser scanning cytometer
(LSC). Clin Chem Lab Med. 2001;39(9):811–7.
37. Van der Auwera I et al. Circulating tumour cell detection: a direct comparison
between the Cell Search System, the AdnaTest and CK-19/mammaglobin RT-
PCR in patients with metastatic breast cancer. Br J Cancer. 2010;102(2):276–84.
38. Andreopoulou E et al. Comparison of assay methods for detection of
circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest
BreastCancer Select/Detect versus Veridex Cell Search system. Int J Cancer.
2012;130(7):1590–7.
39. Muller V et al. Prognostic impact of circulating tumor cells assessed with
the Cell Search System and AdnaTest Breast in metastatic breast cancer
patients: the DETECT study. Breast Cancer Res. 2012;14(4):R118.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Jueckstock et al. BMC Cancer  (2016) 16:401 Page 11 of 11
